[HTML][HTML] Polymerase-mediated ultramutagenesis in mice produces diverse cancers with high mutational load

HD Li, I Cuevas, M Zhang, C Lu… - The Journal of …, 2018 - Am Soc Clin Investig
HD Li, I Cuevas, M Zhang, C Lu, MM Alam, YX Fu, MJ You, EA Akbay, H Zhang
The Journal of Clinical Investigation, 2018Am Soc Clin Investig
Mutations underlie all cancers, and their identification and study are the foundation of cancer
biology. We describe what we believe to be a novel approach to mutagenesis and cancer
studies based on the DNA polymerase ε (POLE) ultramutator phenotype recently described
in human cancers, in which a single amino acid substitution (most commonly P286R) in the
proofreading domain results in error-prone DNA replication. We engineered a conditional
PoleP286R allele in mice. PoleP286R/+ embryonic fibroblasts exhibited a striking mutator …
Mutations underlie all cancers, and their identification and study are the foundation of cancer biology. We describe what we believe to be a novel approach to mutagenesis and cancer studies based on the DNA polymerase ε (POLE) ultramutator phenotype recently described in human cancers, in which a single amino acid substitution (most commonly P286R) in the proofreading domain results in error-prone DNA replication. We engineered a conditional PoleP286R allele in mice. PoleP286R/+ embryonic fibroblasts exhibited a striking mutator phenotype and immortalized more efficiently. PoleP286R/+ mice were born at Mendelian ratios but rapidly developed lethal cancers of diverse lineages, yielding the most cancer-prone monoallelic model described to date, to our knowledge. Comprehensive whole-genome sequencing analyses showed that the cancers were driven by high base substitution rates in the range of human cancers, overcoming a major limitation of previous murine cancer models. These data establish polymerase-mediated ultramutagenesis as an efficient in vivo approach for the generation of diverse animal cancer models that recapitulate the high mutational loads inherent to human cancers.
The Journal of Clinical Investigation